Blockchain provides real-time visibility into the entire clinical trial supply chain and has the potential to solve several of the industry’s biggest challenges. (outsourcing-pharma.com)
New machine learning tool could reduce clinical trial attrition
Cambridge Consultants has designed a digital health tool that aims to help prevent patients becoming stressed and dropping out of clinical trials. The tool, known as Verum, uses biometric data and machine learning to measure and monitor a participant’s stress levels during trials, enabling trial coordinators to intervene and mitigate the effect of stress on compliance. (pharmaphorum)
Mitsubishi Tanabe Pharma and Hitachi use AI to speed up drug R&D
Mitsubishi Tanabe Pharma and Hitachi have become the latest example of pharma and tech companies coming together and using artificial intelligence (AI) to improve the drug development process. Hitachi has developed AI technology for automated information search and collection, which has shortened by 70% Mitsubishi’s time spent collecting information from medical papers and other sources in designing clinical trials. (pharmaphorum)
GSK platform could reduce drug discovery process from years to minutes
GlaxoSmithKline (GSK) recently implemented a new platform that integrates and standardizes all of their data across their R&D division, which will transform the way they do drug discovery and clinical trials. The platform promises to completely change the drug discovery process and narrow down what usually takes a few years to 30 minutes. (Drug Discovery & Development)
Predictions for 2018: A radical rethinking of the clinical trials process
From the Editor in Chief, Fortune. His predictions of three developing trends for the new year include, among others, a radical rethinking of the clinical trials process. This year, we will have a new tool to explore in the clinical research setting: artificial intelligence, which will allow us to use computer learning to better anticipate which drugs will work well in any one person. (Fortune)
AI and machine learning may double the odds of success of clinical trials
On November 21, Clinical Research Currents had the opportunity to interview Travis May, Co-Founder and CEO, Datavant As a technologist looking at the biopharma industry, it’s surprising and disconcerting how little data is shared. Biopharmaceutical data is siloed across big pharma companies, universities, healthcare consortia, CROs, research groups, hospital systems, regulatory Read more
Cambridge Healthtech Institute will launch inaugural conference on AI in clinical trials
Artificial Intelligence and Machine Learning in Clinical Research:
AI, ML, ROBOTICS, ADVANCED ANALYTICS, BIG DATA
FEBRUARY 14-15, 2018 | HYATT REGENCY ORLANDO | ORLANDO, FL
Artificial intelligence (AI) and machine learning (ML) have propelled many industries and are now starting to make their way into clinical research. Many pharmaceutical companies and CROs are starting projects involving some elements of AI, ML and robotic process automation in clinical trials. Cambridge Healthtech Institute (CHI) will launch this inaugural conference, part of the 9th Annual SCOPE Summit, to accelerate the adoption of these approaches in clinical trials. (scopesummit.com)
Pharma companies are recruiting top talent from tech giants like Google and LinkedIn
GlaxoSmithKline, Johnson & Johnson, and other pharma companies are actively recruiting technologists from companies like Google and Microsoft’s LinkedIn, to help modernize the processes that big pharma uses to discover and develop new drugs. According to a GSK spokesperson, there are plenty of opportunities for tech workers to build machine learning tools that analyze health information. An ongoing project may use previously-collected clinical trial data as an alternative to a control arm in a study, which could potentially reduce the cost of clinical trials and provide a better patient experience. (CNBC)
IBM Watson, CDC hunting for new blockchain applications for healthcare
The Centers for Disease Control and Prevention (CDCP) has signed on with IBM Watson Health to explore new applications for blockchain in healthcare. IBM says this is an expansion of its existing work with the U.S. FDA, which is exploring potential blockchain applications for EHRs, clinical trials, internet-of-things, genomics and more. Blockchain technology offers a high level of security, and when combined with AI holds big promise for managing patient data. (HealthcareITNews)